Marinus Pharmaceuticals (NASDAQ:MRNS) Coverage Initiated by Analysts at StockNews.com

by · The Cerbat Gem

StockNews.com started coverage on shares of Marinus Pharmaceuticals (NASDAQ:MRNS – Free Report) in a report released on Tuesday morning. The brokerage issued a hold rating on the biopharmaceutical company’s stock.

Several other brokerages have also recently issued reports on MRNS. Cantor Fitzgerald reissued an “overweight” rating and set a $4.00 price objective on shares of Marinus Pharmaceuticals in a research note on Thursday, November 14th. HC Wainwright reissued a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. TD Cowen restated a “hold” rating on shares of Marinus Pharmaceuticals in a report on Friday, October 25th. Truist Financial cut Marinus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, October 24th. Finally, LADENBURG THALM/SH SH lowered shares of Marinus Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Wednesday, August 14th. Nine equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $4.79.

Read Our Latest Analysis on Marinus Pharmaceuticals

Marinus Pharmaceuticals Stock Performance

MRNS opened at $0.32 on Tuesday. Marinus Pharmaceuticals has a 1 year low of $0.26 and a 1 year high of $11.26. The company’s 50 day simple moving average is $1.01 and its 200 day simple moving average is $1.24. The stock has a market capitalization of $17.93 million, a PE ratio of -0.13 and a beta of 1.26.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Renaissance Technologies LLC acquired a new stake in Marinus Pharmaceuticals during the 2nd quarter valued at $727,000. Vanguard Group Inc. grew its stake in shares of Marinus Pharmaceuticals by 5.0% during the first quarter. Vanguard Group Inc. now owns 2,805,920 shares of the biopharmaceutical company’s stock valued at $25,366,000 after acquiring an additional 132,689 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in shares of Marinus Pharmaceuticals during the second quarter worth about $813,000. Hussman Strategic Advisors Inc. increased its position in shares of Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 10,500 shares during the last quarter. Finally, Squarepoint Ops LLC acquired a new position in shares of Marinus Pharmaceuticals in the second quarter worth about $206,000. 98.80% of the stock is owned by institutional investors and hedge funds.

About Marinus Pharmaceuticals

(Get Free Report)

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.

Featured Articles